论文部分内容阅读
目的 探讨国产紫杉醇及长春瑞宾加顺铂及卡铂联合方案对晚期非小细胞肺癌 (NSCLC)的疗效和毒副反应。方法 选取初治晚期NSCLC 181例 ,分别应用NP(长春瑞宾 +顺铂 )、TC(国产紫杉醇 +卡铂 )及TP(国产紫杉醇 +顺铂 )方案治疗。每例均完成两周期化疗后评价疗效及毒副反应。结果 三组患者近期有效率分别为NP组 42 .4%,TC组 40 .3 %,TP组 43 .3 %,三组间有效率比较均无显著性差异 ( χ2 =0 .10 86,P >0 .0 5 )。NP组中位生存期为 8.4个月 ,TC组 9.4个月 ,TP组 8.9个月 (P >0 .0 5 )。NP组 1、2、3年生存率分别为 3 9.0 %、16.9%、5 .1%;TC组分别为 41.9%、2 1.0 %、6.5 %;TP组分别为 40 .0 %、18.3 %、5 .0 %,三组间比较无统计学差异 ( χ2 =0 .14 0 4,P >0 .0 5 )。三组毒副反应均以骨髓抑制、脱发及恶心呕吐为主 ,但均未影响治疗。三组病例均无化疗相关死亡发生。结论 NP、TC及TP联合方案是治疗晚期NSCLC有效且耐受性较好的方案
Objective To investigate the efficacy and side effects of domestic paclitaxel combined with vinorelbine plus cisplatin and carboplatin for advanced non-small cell lung cancer (NSCLC). Methods 181 patients with newly diagnosed advanced non-small cell lung cancer (NSCLC) were enrolled and treated with NP (vinorelbine + cisplatin), TC (domestic paclitaxel + carboplatin) and TP (domestic paclitaxel + cisplatin) respectively. Each case was completed after two cycles of chemotherapy to evaluate efficacy and toxicity. Results The effective rates of the three groups were 42.4% in the NP group, 40.3% in the TC group and 43.3% in the TP group, respectively, with no significant difference between the three groups (χ2 = 0.1086, P > 0 .0 5). The median survival time was 8.4 months in the NP group, 9.4 months in the TC group and 8.9 months in the TP group (P> 0.05). The 1, 2, 3-year survival rates of NP group were 39.0%, 16.9% and 5.1% respectively, while those in TC group were 41.9%, 2.01% and 6.5%, respectively; those in TP group were 40.0% and 18.3% 5%. There was no significant difference among the three groups (χ2 = 0.14 0 4, P> 0.05). Three groups of side effects are bone marrow suppression, hair loss and nausea and vomiting, but did not affect the treatment. No chemotherapy-related death occurred in all three groups. Conclusions NP, TC and TP combination regimens are effective and well tolerated in advanced NSCLC